Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association
Esperion Therapeutics to Deliver Three Scientific Poster Presentations at the 2014 Annual Scientific Sessions of the National Lipid Association
May 1, 2014
The first, poster 155, "ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients across Four Phase 2a Studies," concludes ETC-1002 significantly lowered low-density lipoprotein cholesterol (LDL-C), reduced high sensitivity C-reactive protein (hsCRP), and was well-tolerated in the four studies.
The second, poster 156, "ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients with Statin Intolerance," concludes ETC-1002 demonstrated a 32 percent lowering of LDL-C, and a reduction of 42 percent in hsCRP levels in patients who had failed two or more statins due to muscle-related side effects. ETC-1002 was also well-tolerated, and muscle-related adverse events were similar in the ETC-1002 and placebo groups.
The third and final, poster 172, "ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure," showed that ETC-1002 significantly reduced systolic blood pressure by 6.68 mmHg compared to placebo in a pooled post hoc sub-group analysis of four phase 2a studies in hypercholesterolemic patients with mildly elevated blood pressure.
"As we continue to advance ETC-1002 for LDL-C lowering in
hypercholesterolemic patients who are intolerant to statins," said
All three posters will be presented during two scheduled sessions;
About
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of ETC-1002 and
the anticipated timing for reporting top-line results from Esperion's
Phase 2b ETC-1002-008 clinical study and Esperion's Phase 2b
ETC-1002-009 clinical study. Any statements contained in this press
release that are not statements of historical fact may be deemed to be
forward-looking statements. Forward-looking statements involve risks and
uncertainties that could cause Esperion's actual results to differ
significantly from those projected, including, without limitation, the
risk that unanticipated developments could interfere with the
development (and commercialization) of ETC-1002, as well as other risks
detailed in Esperion's filings with the
Media Contact:
efox@w2ogroup.com
Source:
News Provided by Acquire Media